1. Home
  2. LGHL vs ENTO Comparison

LGHL vs ENTO Comparison

Compare LGHL & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGHL
  • ENTO
  • Stock Information
  • Founded
  • LGHL 2015
  • ENTO 2014
  • Country
  • LGHL Singapore
  • ENTO United States
  • Employees
  • LGHL N/A
  • ENTO N/A
  • Industry
  • LGHL Investment Bankers/Brokers/Service
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGHL Finance
  • ENTO Health Care
  • Exchange
  • LGHL Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • LGHL 1.4M
  • ENTO 1.2M
  • IPO Year
  • LGHL N/A
  • ENTO 2016
  • Fundamental
  • Price
  • LGHL $0.19
  • ENTO $0.44
  • Analyst Decision
  • LGHL
  • ENTO
  • Analyst Count
  • LGHL 0
  • ENTO 0
  • Target Price
  • LGHL N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • LGHL 2.8M
  • ENTO 225.8K
  • Earning Date
  • LGHL 12-04-2024
  • ENTO 11-13-2024
  • Dividend Yield
  • LGHL N/A
  • ENTO N/A
  • EPS Growth
  • LGHL N/A
  • ENTO N/A
  • EPS
  • LGHL N/A
  • ENTO N/A
  • Revenue
  • LGHL $18,678,142.00
  • ENTO N/A
  • Revenue This Year
  • LGHL N/A
  • ENTO N/A
  • Revenue Next Year
  • LGHL N/A
  • ENTO N/A
  • P/E Ratio
  • LGHL N/A
  • ENTO N/A
  • Revenue Growth
  • LGHL N/A
  • ENTO N/A
  • 52 Week Low
  • LGHL $0.17
  • ENTO $0.19
  • 52 Week High
  • LGHL $1.55
  • ENTO $14.51
  • Technical
  • Relative Strength Index (RSI)
  • LGHL 45.31
  • ENTO 36.19
  • Support Level
  • LGHL $0.18
  • ENTO $0.43
  • Resistance Level
  • LGHL $0.21
  • ENTO $0.68
  • Average True Range (ATR)
  • LGHL 0.02
  • ENTO 0.07
  • MACD
  • LGHL 0.00
  • ENTO -0.03
  • Stochastic Oscillator
  • LGHL 36.14
  • ENTO 1.46

About LGHL Lion Group Holding Ltd.

Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: